Redhill Biopharma Ltd. American Depositary Shares (RDHL)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I start with the business, not the stock chart. RedHill is a tiny specialty biopharma, with 13 employees, selling Talicia for H. pylori and Aemcolo for travelers' diarrhea, plus opaganib and other pipeline candidates. That is a difficult arena with regulatory risk and limited evidence of a durable moat. At the 2026-10-13 close of $0.51, market value is only $4.6 million, and FairStock's P/B calculation is 0.61, which might hint at a bargain if book value is solid. But the quality markers are ugly: FairStock's ROCE is -22.38%, its Piotroski F-Score is 0/9, its Altman Z-Score is -23.33, and its FairStock Score is 20/100. Debt/equity of 0.25 is not terrifying by itself, but negative returns and severe distress-score readings demand scrutiny. There is no P/E because earnings are not meaningful; EPS is listed as $0.00, and revenue and profit growth data are unavailable. The Lynch classification is none, because only 0 years of filed annual results exist and three are needed. A beta of 4.90 signals extreme volatility, echoed by the 52-week range of $0.44-$2.14. Future growth depends on commercial execution and clinical wins, especially opaganib, but those are binary events. I would want filed revenue, cash runway, and share-count evidence before calling this cheap. A low price and sub-book multiple are not enough when the business earns negative returns and carries a distress-score profile. This looks speculative.

In plain English: It makes stomach and infectious-disease medicines and is developing new ones. The business looks weak: it is very small, has no clear profits in the data, and carries high financial risk. The 51-cent price is low, but the numbers do not show a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer